Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HGF R


Brief Information

Name:Hepatocyte growth factor receptor
Target Synonym:EC 2.7.10,EC:,HGF receptor,HGF/SF receptor,Hepatocyte growth factor receptor,Tyrosine-protein kinase Met,MET,SF receptor,Scatter factor receptor,MET Proto-Oncogene, Receptor Tyrosine Kinase,Proto-Oncogene C-Met,Met Proto-Oncogene,EC,DFNB97,AUTS9,RCCP2,C-Met,HGFR,Proto-Oncogene Proteins c-met
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:44
Lastest Research Phase:Approved


Project item Indications Research phase Cooperation demands
BNO202202 Gastric cancer, solid tumor IND Approval License-out or co-development

Product ListCompare or Buy

Part of Bioactivity data

FITC-Labeled Human HGF R, His TagFITC-Labeled Human HGF R, His Tag (Cat. No. HGR-HF224) ELISA bioactivity

Immobilized Human HGF, Fc Tag (Cat. No. HGF-H5253) at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human HGF R, His Tag (Cat. No. HGR-HF224) with a linear range of 0.625-10 μg/mL (QC tested).

HGF R MALS images

The purity of Canine HGF R,Fc Tag(Cat. No. MET-C5256) is more than 90% and the molecular weight of this protein is around 290-320 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name



The SARS-CoV-2 Spike S2-coupled Magnetic Beads is produced by coupling biotinylated SARS-CoV-2 spike S2 protein to streptavidin-conjugated magnetic beads. Because Streptavidin (SA) has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the SA beads irreversibly. The pre-coupled beads are ready to use for capturing anti-SARS-CoV-2 antibody or ACE2 protein from your sample with high specificity.

Clinical and Translational Updates

Related Molecule


Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Amivantamab JNJ-372; JNJ-61186372 Approved Janssen Global Services Llc, Genmab RYBREVANT Canada Carcinoma, Non-Small-Cell Lung Janssen Inc 2021-05-21 Carcinoma, Non-Small-Cell Lung Details
Ensartinib Hydrochloride X-396 Approved Xcovery 贝美纳 Mainland China Carcinoma, Non-Small-Cell Lung Betta Pharmaceuticals Co Ltd 2020-11-17 Solid tumours; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Savolitinib HM-5016504; AZD-6094; HMP-504; HMPL-504 Approved Hutchison Medipharma Ltd 沃瑞沙, ORPATHYS Mainland China Carcinoma, Non-Small-Cell Lung Hutchison Huangpu Medicine (Shanghai) Co Ltd 2021-06-22 Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Capmatinib Hydrochloride NVP-INC280-NX; INCB-28060; C2A374O70X; INC-280; INCB-028060 Approved Novartis Pharma Ag, Incyte Corp Tabrecta Japan Carcinoma, Non-Small-Cell Lung Novartis Pharma Ag 2020-05-06 Liver Neoplasms; Solid tumours; Carcinoma; Adenocarcinoma of Lung; Neoplasms; Triple Negative Breast Neoplasms; Hepatic Insufficiency; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis Details
Tepotinib hydrochloride hydrate EMD-1214063; MSC-2156119; MSC-2156119J Approved Merck Serono Tepmetko, テプミトコ, TEPMETKO EU Carcinoma, Non-Small-Cell Lung Merck KGaA, Darmstadt, Germany 2020-03-25 Solid tumours; Hepatic Insufficiency; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Crizotinib PF-1066; PF-2341066; PF-02341066; PF-002341066 Approved Pfizer Pharmaceuticals Ltd (China) 赛可瑞, Xalkori United States Lymphoma, Large-Cell, Anaplastic Pf Prism Cv 2011-08-26 Colorectal Neoplasms; Neoplasm Metastasis; Neurilemmoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lung Neoplasms; Ureteral Neoplasms; Solid tumours; Urethral Neoplasms; Neuroblastoma; Uveal melanoma; Urinary Bladder Neoplasms; Myofibroma; Multiple Myeloma; Kidney Diseases; Neurofibromatosis 2; Neoplasms; Hematologic Neoplasms Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Thyroid Neoplasms; Adenocarcinoma, Follicular; Brain Neoplasms; Sarcoma; Neuroblastoma; Neurofibroma, Plexiform; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Bile Duct Neoplasms; Central Nervous System Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Thyroid Cancer, Papillary; Meningioma; Carcinoma, Transitional Cell; Kidney Neoplasms; Ovarian germ cell tumor; Bone metastases; Carcinoma, Renal Cell; Rejection of liver transplantation; Esophageal Neoplasms; Pain; Stomach Neoplasms; Carcinoma, Merkel Cell; Glioblastoma; Seminoma; Solid tumours; Neurofibromatoses; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Papillary; Skin Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Adrenocortical Carcinoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SAIT-301 SAIT-301 Phase 1 Clinical Neoplasms Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 Phase 1 Clinical Shijiazhuang No 4 Pharmaceutical Co Ltd, Nanjing Nadingfei Pharmaceutical Technology Co Ltd Liver Neoplasms; Solid tumours; Stomach Neoplasms; Lung Neoplasms Details
LMV-12(HE003) LMV-12(HE003) Phase 1 Clinical Nanchang Hongyi Technology Co Ltd Solid tumours Details
Pamufetinib TAS-115 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Neoplasms Details
NP-107 NP107; NP-107 Phase 1 Clinical Shanghai Nawei Biotechnology Co Ltd Solid tumours Details
Boxitinib Hydrochloride Phase 1 Clinical Hec Pharm Co Ltd Stomach Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Glioma; Lung Neoplasms Details
CM-118 CM-118 Phase 1 Clinical Xcovery Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AL-2846 AL-2846 Phase 2 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Advenchen Laboratories Nanjing Ltd Bone metastases; Liver Neoplasms; Stomach Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Neurofibroma; Neoplasms; Medullary thyroid cancer (MTC); Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neurofibromatosis 1 Details
Bozitinib PLB-1001; CBT-101; APL-101; CBI-3103 Phase 2 Clinical Beijing Purunao Biotechnology Co Ltd, Crown Bioscience, Cbt Solid tumours; Ganglioglioma; Carcinoma, Non-Small-Cell Lung Details
Emibetuzumab LA-480; LY-2875358 Eli Lilly And Company Details
GST-HG161 GST-HG161 Phase 1 Clinical Wuxi Apptec Co Ltd, Fujian Cosunter Pharmaceutical Co Ltd Neoplasms; Carcinoma, Hepatocellular Details
RC-108 RC-108; RC108 Phase 1 Clinical RemeGen Co Ltd Solid tumours Details
Alirinetide GM-606; GM-607; GM-608; GM-609; GM-6; GM-600; GM-602; GM-603; GM-604; GM-605 Genervon Biopharmaceuticals Llc Details
LM-061 LM-061 Phase 1 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Solid tumours Details
ASKC-202 ASKC202 Phase 1 Clinical Jiangsu Aosaikang Pharmaceutical Co Ltd Solid tumours Details
REGN-5093 REGN-5093 Regeneron Pharmaceuticals Inc Details
HTI-1066 HTI-1066 Jiangsu Hengrui Medicine Co Ltd Details
SGX-523 SGX-523 Eli Lilly And Company Details
Elzovantinib TPX-0022 Phase 2 Clinical Turning Point Therapeutics Inc Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Bafisontamab FIT-013a; EMB-01 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Fosgonimeton ATH-1017; NDX-1017 M3 Biotechnology Details
Altiratinib DP-5164; DCC-2701; DCC-22701; T-678746713 Deciphera Details
TR1801-ADC MT-8633; TR1801-ADC Tanabe Research Laboratories Usa Details
telisotuzumab Mab224G11; Mabh224G11; h224G11; ABT-700 Pierre Fabre Details
HLX-55 HLX-55; KTN-0216 Phase 1 Clinical Kolltan Pharmaceuticals Inc Solid tumours Details
Glesatinib MG-90265; MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly Mirati Therapeutics Details
Refanalin ANG-3777; BB-3; SNV-003 Vifor Pharma Ag, Angion Biomedica Details
LY-3164530 LY-3164530 Eli Lilly And Company Details
AMG-208 AMG-208 Amgen Inc Details
Recombinant plasmid-hepatocyte growth factor Pudk-HGF Phase 3 Clinical Academy Of Military Medical Sciences, Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd Ischemia; Peripheral Arterial Disease Details
REGN-5093-M114 METxMET-M114; REGN5093-M114 Regeneron Pharmaceuticals Inc Details
ABN-401 ABN-401; KDDF-201603-08 Abion Inc Details
BPI-9016 BPI-9016; BPI-9016M Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
CBT-101 CBT-101 Crown Bioscience Details
EMD-1204831 EMD-1204831 Merck Serono Details
RXDX-106 RXDX-106 Teva, Daiichi Sankyo Co Ltd Details
PF-04217903 PF-4217903; PF-04217903; PF-4217903-A Pfizer Pharmaceuticals Ltd (China) Details
JNJ-38877605 JNJ-38877605 Johnson & Johnson Details
Merestinib LY-2801653; 5OGS5K699E Eli Lilly And Company Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) The Second Hospital Of Nanjing Medical University Details
MCLA-129 MCLA-129 Phase 2 Clinical Merus Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Anti-cMet SIMPLE Antibody ARGX-111 Argenx Se Details
JNJ-38877618 OMO-1; JNJ-38877618 Johnson & Johnson Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 1 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase 1 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
Sym-015 Sym-015 Phase 2 Clinical Symphogen Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Kanitinib CX-1003 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd Solid tumours Details
HS-10241 HS-10241 Phase 1 Clinical Jiangsu Hansoh Pharmaceutical Group Co Ltd Solid tumours; Carcinoma; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Telisotuzumab vedotin ABT-399; ABBV-399 Phase 3 Clinical Abbvie Inc Solid tumours; Carcinoma, Non-Small-Cell Lung Details
XL-092 XL-092 Phase 3 Clinical Exelixis Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms Details
Sitravatinib IND-155305; MG-516; MG-91516; MGCD-516 Phase 3 Clinical Mirati Therapeutics Ureteral Neoplasms; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Mouth Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Hepatic Insufficiency; Solid tumours; Breast Neoplasms; Liposarcoma; Lung Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Biliary Tract Neoplasms Details
CKD-702 Phase 1 Clinical Chong Kun Dang Pharmaceutical Corp Carcinoma, Non-Small-Cell Lung Details
SPH3348 SPH-3348 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Solid tumours; Neoplasms Details
GB-263 GB-263; GB-263T Phase 2 Clinical Genor Biopharma Co Ltd Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message